NASDAQ:AGLE - Aeglea BioTherapeutics, Inc.
$8.45
 $0.29
+3.55%
1:45PM EDT
2019-02-15
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  AGLE     avg for
industry  
  avg for
sector  
42 stocks weight:  33. 79   0. 01   3. 19  
42 stocks rank:  3. 22 K 2. 01 K 1. 09 K
# analyst opinions:  6. 00   14. 84   14. 43  

quick ratio:  8. 94   5. 33   1. 80  
current ratio:  9. 37   5. 64   2. 19  

target price low:  10. 00   89. 87   116. 44  
target price avg:  10. 50   116. 13   140. 62  
target price high:  18. 67   144. 13   161. 60  
1-yr high:  11. 11   124. 91   142. 18  
last close:  7. 80   101. 33   125. 34  
50-day avg:  8. 19   98. 45   122. 34  
200-day avg:  9. 15   99. 87   122. 31  
1-yr low:  5. 97   77. 93   99. 86  
volume:  209. 01 K 2. 40 M 4. 39 M
50-day avg volume:  134. 93 K 3. 29 M 4. 86 M
200-day avg volume:  205. 58 K 3. 21 M 4. 16 M

1-day return:  -0. 38 % 0. 35 % -0. 08 %
this week return:  -0. 38 % 0. 46 % -0. 07 %
12-wk return:  -2. 38 % 5. 59 % 1. 56 %
52-wk return:  32. 94 % -0. 88 % 14. 91 %

enterprise value (EV):  122. 89 M 54. 52 B 102. 18 B
market cap:  186. 77 M 48. 30 B 93. 12 B
EBITDA:  -36. 50 M 4. 78 B 7. 07 B
enterprise multiple (EV/EBITDA):  -3. 37   -88. 47   2. 58  
enterprise/revenue (EV/R):  22. 88   30. 50   23. 55  
total revenue:  5. 37 M 11. 17 B 39. 03 B
total debt:  0. 00   13. 63 B 16. 46 B
net income (common):  -35. 93 M 2. 34 B 3. 51 B

shares outstanding:  23. 94 M 601. 87 M 1. 19 B
shares:  10. 63 M 599. 22 M 1. 12 B
shares short:  718. 23 K 11. 51 M 12. 17 M
shares short prior month:  449. 06 K 11. 81 M 13. 15 M
short ratio:  5. 25   4. 63   2. 90  
short % of float:  3. 87 % 6. 17 % 2. 78 %
total cash/share:  2. 70   12. 23   11. 30  
total cash:  64. 73 M 7. 42 B 7. 19 B
free cash flow:  -18. 64 M 94. 45 M 2. 03 B
operating cash flow:  -30. 87 M 161. 90 M 3. 01 B

book value:  2. 88   14. 36   28. 94  
price/book:  2. 71   -1. 54   -2. 98  
gross profits:  -17. 61 M 8. 20 B 15. 98 B
operating margins:  -684. 99 % -468. 22 % -616. 90 %
EBITDA margins:  0. 00 % 13. 04 % 22. 45 %
profit margins:  0. 00 % 6. 01 % 9. 83 %
gross margins:  0. 00 % 48. 26 % 54. 52 %

1-yr max volatility:  -19. 15 % --- ---
1-yr mean volatility:  0. 25 % 0. 02 % 0. 07 %

1-yr EPS:  -1. 89   2. 91   4. 09  
forward EPS:  -2. 22   4. 19   6. 88  
P/E:  -4. 12   4. 76   27. 05  
forward P/E:  -3. 53   7. 25   10. 02  
PE/G:  0. 42   1. 60   5. 54  
growth:  -9. 73 % 630. 40 % 97. 64 %
earnings high:  -0. 15   1. 24   1. 63  
earnings avg:  -0. 37   0. 98   1. 51  
earnings low:  -0. 52   0. 73   1. 38  
revenue high:  5. 50 M 2. 84 B 10. 79 B
revenue avg:  1. 98 M 2. 75 B 10. 45 B
revenue low:  -0. 00   2. 64 B 10. 25 B
return on assets:  -34. 89 % -3. 52 % 3. 78 %
return on equity:  -60. 30 % 105. 21 % 25. 65 %
revenue/share:  0. 28   14. 46   58. 94  

beta (1yr vs S&P500):  0. 22   1. 22   0. 94  
sharpe (1yr):  0. 88   0. 20   1. 02  

held % insiders:  9. 68 % 6. 52 % 3. 28 %
held % institutions:  75. 87 % 79. 51 % 70. 64 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-11 : AGLE
.    + 0.899 =         0.899 :: INITIAL WEIGHT
.  + 540.503 =       541.402 :: inverse volume-to-price addition
.  + 441.468 =       982.869 :: spline projection addition
.  - 147.522 =       835.347 :: poor performance penalty
.    x 1.431 =      1195.542 :: one-year gains+dividend factor
.    x 3.459 =      4135.261 :: 13 weeks' performance factor
.    x 1.494 =      6176.383 :: industry recommendation factor
.     x 1.75 =     10810.775 :: EV/R factor
.    x 0.997 =     10773.054 :: return on assets factor
.    x 0.994 =     10708.096 :: return on equity factor
.    x 2.339 =     25045.248 :: current ratio factor
.    x 1.061 =     26576.396 :: quick ratio factor
.    x 1.091 =     28997.226 :: short ratio factor
.    x 2.027 =     58779.248 :: price-to-book factor
.    x 2.174 =    127803.611 :: P/E weight
.     x 1.24 =    158449.572 :: PE/G factor
.    x 1.529 =    242328.391 :: beta factor
.    x 0.881 =    213423.113 :: sharpe factor
.    x 1.555 =    331903.786 :: target low factor
.    x 1.196 =    397046.397 :: target mean factor
.    x 1.118 =    443917.884 :: target high factor
.    x 1.056 =    468728.477 :: industry 12-weeks return
.    x 0.998 =    467724.834 :: "drift" penalty 1 days ago
.    x 0.784 =    366907.199 :: "drift" penalty 2 days ago
.    x 0.994 =    364631.095 :: "drift" penalty 3 days ago
.    x 0.999 =    364292.153 :: overall "drift" factor
.    x 0.999 =    363997.815 :: largest single-day jump factor
.    x 0.107 =     38805.737 :: low price factor
.      x 1.0 =     38807.997 :: factor hist industry gain for week 06
.   cubeRoot =        33.856 :: reduced for readability
.                     33.856 :: FINAL WEIGHT for NASDAQ:AGLE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org